Hydrocephalus is a condition characterized by the buildup of cerebrospinal fluid in the brain, resulting in elevated intracranial pressure. Hydrocephalus shunts, typically implanted via surgical procedures, consist of tube and valve systems that divert excess cerebrospinal fluid from the brain's ventricles to another part of the body, often the abdominal cavity, where it can be reabsorbed. The surging prevalence of hydrocephalus and advancements in hydrocephalus management devices are the key factors driving the market in the US. However, the high cost of treatments and a need for revised surgeries hamper the US hydrocephalus shunts market progress.
In the United States, treatment options for hydrocephalus typically include: Shunt Placement: Shunt systems are commonly used to treat hydrocephalus. A neurosurgeon surgically implants a shunt, which is a device consisting of a tube and a valve, to divert excess cerebrospinal fluid away from the brain to another part of the body where it can be absorbed or reabsorbed.
Endoscopic Third Ventriculostomy (ETV): ETV is another surgical procedure involves creating a small hole in the floor of the third ventricle of the brain to allow cerebrospinal fluid to flow out and be absorbed. ETV is primarily used for certain types of non-communicating hydrocephalus. Ventriculostomy with Catheter: Another surgical option involves inserting a catheter directly into the brain's ventricles to drain excess cerebrospinal fluid.
Revision Surgery: Sometimes, patients with shunts may require revision surgeries to address issues such as blockages, infections, or malfunctions of the shunt system.
Minimally Invasive Techniques: Advancements in minimally invasive procedures, such as endoscopy, have allowed for more precise diagnosis and treatment of hydrocephalus.
Intraventricular Endoscopy: This procedure uses endoscopy to view and treat problems within the ventricular system of the brain.
Monitoring and Adjustments: Regular monitoring of shunt function and intracranial pressure is important. Adjustments to shunt settings may be made to optimize treatment.
Experimental and Research-Based Treatments: In some cases, patients may have the option to participate in clinical trials or experimental treatments being investigated by medical researchers. It's important to note that the choice of treatment depends on various factors, including the type of hydrocephalus, the patient's age, overall health, and individual circumstances. Treatment decisions are typically made in consultation with neurosurgeons and other medical specialists who specialize in the management of hydrocephalus.
Hydrocephalus is a chronic neurological disease caused by an abnormal cerebrospinal fluid (CSF) deposition in the cavities (ventricles) of the brain. According to the Hydrocephalus Association, over 1 million people in the US are likely to live with hydrocephalus by 2023, while 1 in 770 babies would develop hydrocephalus yearly. Similarly, as per the article "Navigating the Ventricles: New Insights into the Pathogenesis of Hydrocephalus," published in Elsevier, congenital hydrocephalus occurs in 1 in 500–1,000 babies born in the US. Stroke, intraventricular and subarachnoid hemorrhage, brain tumors, traumatic brain injury, and craniectomy can lead to acquired hydrocephalus. According to a study titled “Management of Hydrocephalus in Children: Anatomic Imaging Appearances of CSF Shunts and Their Complications,” published in the American Journal of Roentgenology in 2020, hydrocephalus affects approximately 1–2% of the US population and results in 70,000 hospitalizations, with the placement of 18,000–33,000 CSF shunts. The annual healthcare expenditures in the country are approximately US$ 2 billion.
The treatment method of hydrocephalus mainly focuses on managing CSF through shunts. There are several forms of treatment for removing excess CSF; the placement of a ventriculoperitoneal (VP) shunt is a common method. The shunts help in removing excess CSF from the brain and then divert it to the other parts of the body, wherein it is absorbed during the circulatory process. According to a study titled “Ventriculoperitoneal Shunts in the Emergency Department,” published in the National Library of Medicine, ~30,000 VP shunt procedures are performed annually in the US. An article published on hydrocephalus and shunts in Ausmed Education states that 33,000 people are implanted with shunts annually in this country. Thus, the high incidence of hydrocephalus drives the demand for hydrocephalus shunts in the US, thereby boosting the US hydrocephalus shunts market growth in this country.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 109.61 Million |
| Market Size by 2030 | US$ 146.24 Million |
| Global CAGR (2022 - 2030) | 3.7% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Product
|
| Regions and Countries Covered | United States
|
| Market leaders and key company profiles |
The List of Companies - US Hydrocephalus Shunts Market
Shunt, the surgical insertion of a drainage system is the most common remedy for hydrocephalus. It drains extra cerebrospinal fluid from the brain to another part of the body such as the abdomen, where it can be more easily absorbed. It consists of a long and flexible tube with a valve that keeps fluid from the brain flowing in the right approach and at the proper rate.
The hydrocephalus valves segment held the largest market share of the market in the US hydrocephalus shunts market in 2022.
Key factors that are driving the growth of this market are the surging prevalence of hydrocephalus and growing advancements in hydrocephalus valves.
The CAGR value of the hydrocephalus shunts market during the forecasted period of 2020-2030 is 3.9%.
The hydrocephalus shunts market majorly consists of the players such as B. Braun SE, Sophysa SA, Integra LifeSciences Holdings Corp, KANEKA MEDIX CORP., Medtronic Plc, Natus Medical Inc, Anuncia Inc. and Desu Medical among others.